{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:24:13Z","timestamp":1794605053382,"version":"4.9.1"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Cellular therapies such as CD19-targeting CAR T cells are a rapidly evolving field in an area of unmet clinical needs: autoimmune diseases including systemic sclerosis (SSc). The aim of this review is to summarize the available data on safety and efficacy of CAR T-cell therapy in SSc and to discuss upcoming developments and challenges for the near future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Several case reports and series recently described the treatment of SSc patients with CD19-targeting CAR T cells, which resulted in profound B-cell depletion and downregulation of autoimmunity. Encouraging results on efficacy in several disease manifestations were reported including skin and organ fibrosis. Also, vascular phenomena including digital ulcerations improved. The safety profile showed mostly mild-to-moderate cytokine release syndrome (CRS) and low rates of neurotoxicity. Infectious complications ranged from mild upper airway infections to pneumonia. However, a case of herpes simplex reactivation with secondary lethal haemophagocytosis was also described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current evidence suggests very promising effects of CD19-CAR T-cell therapy on several SSc manifestations. Additional larger trials are needed. Current frontiers are patient selection, refining lymphodepletion protocols, and expanding target antigens beyond CD19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001133","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T06:00:10Z","timestamp":1762236010000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["CAR T-cell therapy in systemic sclerosis: the next frontier in immune modulation"],"prefix":"10.1097","volume":"38","author":[{"given":"Panagiotis","family":"Garantziotis","sequence":"first","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Auth","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"R1-20251204","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41584-024-01217-2","article-title":"An international perspective on the future of systemic sclerosis research","volume":"21","author":"Abraham","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20251204","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R3-20251204","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"R4-20251204","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.39865","article-title":"Review: frontiers of antifibrotic therapy in systemic sclerosis","volume":"69","author":"Distler","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R5-20251204","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R6-20251204","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","article-title":"Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls","volume":"51","author":"Guillevin","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20251204","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R8-20251204","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol"},{"key":"R9-20251204","doi-asserted-by":"crossref","first-page":"933468","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front Immunol"},{"key":"R10-20251204","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R11-20251204","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20251204","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R13-20251204","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R14-20251204","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.100454","article-title":"Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis","volume":"37","author":"Bielecki","year":"2010","journal-title":"J Rheumatol"},{"key":"R15-20251204","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/rheumatology\/keac677","article-title":"More to B: the growing evidence to inform targeting B cells in scleroderma","volume":"62","author":"Bosello","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20251204","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"key":"R17-20251204","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/art.41798","article-title":"B-cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis","volume":"73","author":"Numajiri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R18-20251204","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s10067-021-05665-z","article-title":"B cells in systemic sclerosis: from pathophysiology to treatment","volume":"40","author":"Melissaropoulos","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R19-20251204","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1002\/art.24049","article-title":"Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4","volume":"58","author":"Fineschi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R20-20251204","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-20251204","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R22-20251204","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.2008.104299","article-title":"Antifibroblast antibodies from systemic sclerosis patients bind to alpha-enolase and are associated with interstitial lung disease","volume":"69","author":"Terrier","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 3)","key":"R23-20251204","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.5152\/eurjrheum.2020.19131","article-title":"Putative functional pathogenic autoantibodies in systemic sclerosis","volume":"7","author":"Benfaremo","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R24-20251204","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor beta and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R25-20251204","doi-asserted-by":"crossref","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Francois","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R26-20251204","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.imlet.2017.10.007","article-title":"Agonistic antibodies in systemic sclerosis","volume":"195","author":"Moroncini","year":"2018","journal-title":"Immunol Lett"},{"key":"R27-20251204","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R28-20251204","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R29-20251204","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20251204","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R31-20251204","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R32-20251204","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R33-20251204","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"R34-20251204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"R35-20251204","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R36-20251204","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"R37-20251204","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R38-20251204","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19-CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R39-20251204","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMc2403705","article-title":"CAR T-cell therapy in autoimmune disease","volume":"390","author":"Merkt","year":"2024","journal-title":"N Engl J Med"},{"key":"R40-20251204","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2213-2600(25)00159-6","article-title":"Persisting CD19-CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2\u200ayears","volume":"13","author":"Merkt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R41-20251204","doi-asserted-by":"crossref","first-page":"4890.e9","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"R42-20251204","article-title":"CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation","author":"Pecher","year":"2024","journal-title":"EULAR Rheumatology Open"},{"key":"R43-20251204","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R44-20251204","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"R45-20251204","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R46-20251204","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"R47-20251204","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"key":"R48-20251204","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"R49-20251204","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R50-20251204","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R51-20251204","doi-asserted-by":"crossref","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R52-20251204","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"R53-20251204","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","article-title":"Recent advances in lipid nanoparticles for delivery of mRNA","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"R54-20251204","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"R55-20251204","doi-asserted-by":"crossref","first-page":"809754","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front Oncol"},{"key":"R56-20251204","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"R57-20251204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2019Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R58-20251204","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"R59-20251204","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"R60-20251204","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/ijms26020467","article-title":"Exploring CAR T-cell dynamics: balancing potent cytotoxicity and controlled inflammation in CAR T-cells derived from systemic sclerosis and myositis patients","volume":"26","author":"Dingfelder","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R61-20251204","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R62-20251204","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mechan Dis"},{"key":"R63-20251204","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"R64-20251204","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","article-title":"Aggressive lymphoma after CD19 CAR T-cell therapy","volume":"391","author":"Kobbe","year":"2024","journal-title":"N Engl J Med"},{"key":"R67-20251204","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R68-20251204","doi-asserted-by":"crossref","first-page":"4225.e12","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"R69-20251204","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","article-title":"CAR-T cells inflict sequential killing of multiple tumor target cells","volume":"3","author":"Davenport","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R70-20251204","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R71-20251204","doi-asserted-by":"crossref","first-page":"e179433","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"R72-20251204","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/bloodadvances.2022007806","article-title":"Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19-CAR T-cell therapy","volume":"7","author":"Reimann","year":"2023","journal-title":"Blood Adv"},{"key":"R73-20251204","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19-CAR-T cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"R74-20251204","first-page":"451","article-title":"Analysis of antitopoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"56","author":"Henes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R75-20251204","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R76-20251204","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R77-20251204","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ard.2025.05.339","article-title":"OP0337-2005 trajectories of the EUSTAR AI, ACR CRISS and revised CRISS upon CD19. CART treatment in patients with diffuse cutaneous systemic sclerosis","volume":"84","author":"Bergmann","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R78-20251204","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"R79-20251204","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"R80-20251204","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"R81-20251204","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"R82-20251204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R83-20251204","doi-asserted-by":"crossref","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:01:03Z","timestamp":1764860463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001133","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}